Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oregovomab + Hiltonol in Recurrent Advanced Ovarian Cancer
NCT03162562Phase 1Terminated
- Sponsor
- CanariaBio
- Start
- May 2017
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oregovomab in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by CanariaBio. Primary endpoint: Change in laboratory values, physical findings, vital signs, subjective patient experience and treatment-related adverse events. Started May 2017; status: terminated.
02
Drugs
oregovomab
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03162562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162562.